Advertisement

Pericardial Disease

  • Marshall J. GlesbyEmail author
Chapter

Abstract

Prior to the advent of combination antiretroviral therapy, pericardial effusion, pericarditis, and cardiac tamponade were important clinical problems in HIV-infected patients, especially those with AIDS diagnoses. In the current HIV treatment era, clinically significant pericardial disease is uncommon. Infectious causes, primarily mycobacterial, and malignancy are the most common identifiable causes of clinically significant pericardial disease in HIV-infected patients. The evaluation and management of pericardial disease does not differ fundamentally in HIV-infected patients compared to the general population. While uncommon in resource-rich settings, tuberculous pericarditis is a concern in HIV-infected patients, and empiric treatment for this may be a consideration in some clinical settings with negative diagnostic evaluations. The role of adjunctive corticosteroids with antituberculous therapy remains controversial.

Keywords

Pericarditis Pericardial effusion HIV-1 infection Tuberculous pericarditis Cardiac tamponade 

References

  1. 1.
    Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med. 2000;160(5):602–8.CrossRefGoogle Scholar
  2. 2.
    Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation. 1995;92(11):3229–34.CrossRefGoogle Scholar
  3. 3.
    Lind A, Reinsch N, Neuhaus K, et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res. 2011;16(11):480–3.CrossRefGoogle Scholar
  4. 4.
    Ntusi N, O’Dwyer E, Dorrell L, et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging. 2016;9(3):e004430.CrossRefGoogle Scholar
  5. 5.
    LeWinter MM. Clinical practice. Acute pericarditis. N Engl J Med. 2014;371(25):2410–6.CrossRefGoogle Scholar
  6. 6.
    Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 2000;84(2):183–8.CrossRefGoogle Scholar
  7. 7.
    Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. 2004;190(5):869–78.CrossRefGoogle Scholar
  8. 8.
    Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30.CrossRefGoogle Scholar
  9. 9.
    Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232–7.CrossRefGoogle Scholar
  10. 10.
    Glesby MJ. HIV and Cardiovascular Risk. New York: Oxford University Press; 2011.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of MedicineWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations